Small increases in the risk for statin-associated muscle symptoms were observed for patients on high-intensity therapy.
Dietary strategies aimed solely at lowering saturated fat intake may be less effective in reducing cardiovascular disease (CVD) than recommendations for a plant-centered diet.
Researchers investigate whether asymptomatic atherosclerotic CVD can be prevented with an aggressive medical treatment that reduces LDL cholesterol to <60 mg/dl.
Statin prescribing for at-risk individuals decreases among primary care providers as the day progresses, particularly in the afternoon compared with the morning.
HOPE-3 was designed to assess if reducing BP and/or LDL-C would reduce cardiovascular events in study participants at intermediate risk with no prior cardiovascular events.
Omega-3 fatty acids, including eicosapentaenoic acid (EPA) and docosehexaenoic acid (DHA), have been found to be associated with cardiovascular health benefits.
This study aimed to assess the effects of the various elements of metabolic syndrome on carotid plaque destabilization.
In a review and meta-analysis, investigators evaluated the novel fatty acid inhibitor bempedoic acid as a possible treatment for hyperlipidemia.
Austrian researchers investigated the utility of remnant cholesterol as a marker of cardiovascular event risk in coronary artery disease.
Researchers conducted a patient-level pooled analysis from phase 3 trials of inclisiran in patients with familial hypercholesterolemia or ASCVD.